Title.
Development and Validation of a Policy Tree Approach for Optimizing Intravenous Fluids in Critically Ill Patients with Sepsis and Acute Kidney Injury

Author information.
Wonsuk Oh1,2, Kullaya Takkavatakarn1,2,3, Hannah Kittrell1,4, Khaled Shawwa5, Hernando Gomez6, Ashwin S. Sawant1,2,7, Pranai Tandon1,2,8, Gagan Kumar9, Michael Sterling10, Ira Hofer1,2,11, Lili Chan1,2,12, John Oropello13, Roopa Kohli-Seth13, Alexander W Charney1,14, Monica Kraft8, Patricia Kovatch4, John A. Kellum6, Girish N. Nadkarni1,2,12*, Ankit Sakhuja1,2,13*

1. Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
2. Division of Data-Driven and Digital Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
3. Division of Nephrology, Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
4. Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA
5. Division of Nephrology, Department of Medicine, West Virginia University, Morgantown, West Virginia, USA
6. Department of Critical Care Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
7. Division of Hospital Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
8. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA
9. Department of Pulmonary and Critical Care Medicine, Northeast Georgia Medical Center, Gainesville, Georgia, USA

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
10. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

11. Department of Anesthesiology, Perioperative and Pain Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

12. Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

13. Institute for Critical Care Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

14. Departments of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA

* Equal contribution as senior author

**Corresponding author:**

Ankit Sakhuja, MBBS, MS

Division of Data Driven and Digital Medicine,
Department of Medicine
Icahn School of Medicine at Mount Sinai,
New York, NY

Phone: 212-241-6500, Fax: 212-849-2643

Email: ankit.sakhuja@mssm.edu
Abstract

**Purpose:** Intravenous fluids are mainstay of management of acute kidney injury (AKI) after sepsis but can cause fluid overload. Recent literature shows that restrictive fluid strategy may be beneficial in some patients with AKI, however, identifying these patients is challenging. We aimed to develop and validate a machine learning algorithm to identify patients who would benefit from a restrictive fluid strategy.

**Methods:** We included patients with sepsis who developed AKI within 48 hours of ICU admission and defined restrictive fluid strategy as receiving <500mL fluids within 24 hours after AKI. Our primary outcome was early AKI reversal within 48 hours of AKI onset, and secondary outcomes included sustained AKI reversal and major adverse kidney events (MAKE) at discharge. We used a causal forest, a machine learning algorithm to estimate individual treatment effects and policy tree algorithm to identify patients who would benefit by restrictive fluid strategy. We developed the algorithm in MIMIC-IV and validated it in eICU database.

**Results:** Among 2,091 patients in the external validation cohort, policy tree recommended restrictive fluids for 88.2%. Among these, patients who received restrictive fluids demonstrated significantly higher rate of early AKI reversal (48.2% vs 39.6%, p<0.001), sustained AKI reversal (36.7% vs 27.4%, p<0.001) and lower rates of MAKE by discharge (29.3% vs 35.1%, p=0.019). These results were consistent in adjusted analysis.

**Conclusion:** Policy tree based on causal machine learning can identify septic patients with AKI who benefit from a restrictive fluid strategy. This approach needs to be validated in prospective trials.

**Keywords**
Acute Kidney Injury; Restrictive Fluids; Causal Machine Learning; Policy Tree; Individual Treatment Effect

**Take-home message**
Intravenous fluids are the mainstay of management of acute kidney injury (AKI) after sepsis but can cause fluid overload. In this study using two large, distinct critical care databases, we developed and validated a causal machine learning based Policy Tree approach to identify septic patients with AKI who benefit from a restrictive fluid strategy, enhancing early and sustained AKI reversal, and reducing major adverse kidney events at discharge.
INTRODUCTION:

Acute kidney injury (AKI) is seen in over one-third of critically ill patients with sepsis and is associated with worse outcomes[1]. Oliguria, a frequent clinical indicator of AKI, is common in critically ill patients with sepsis who develop AKI[2]. It is also the second most common reason for the administration of intravenous (IV) fluids in critically ill patients[3]. Since the primary emphasis is on volume optimization, IV fluids are a cornerstone in AKI care. Nonetheless, this approach might not be optimal in all patients. Firstly, administration of fluids does not consistently translate into a corresponding increase in urine output[4]. Secondly, reliance on fluid therapy increases the risk of fluid accumulation, frequently resulting in fluid overload. This phenomenon is itself associated with development and exacerbation of AKI[5-7], and increased mortality rates[7].

Thus, a more personalized approach to IV fluid administration in critically ill patients is warranted. A restrictive approach to administration of IV fluids in patients with acute lung injury has shown to be associated with a shorter duration of mechanical ventilation[8]. Similarly, a restrictive fluid approach to resuscitation for septic shock is safe and associated with less fluid overload[9]. More recently, a restrictive approach to use of IV fluids in critically ill patients with AKI has been shown to be associated with lower cumulative fluid balance and lower rates of initiation of dialysis[10].

However, it remains challenging to identify specific patients with AKI who would benefit from a restrictive fluid strategy. We, therefore, conducted this study to identify septic patients with AKI who would benefit from restrictive fluid therapy.

METHODS:

Study Design and Data Sources

We conducted a retrospective study using data from two critical care databases: the Medical Information Mart for Intensive Care IV (MIMIC-IV)[11] and the eICU Collaborative Research Database (eICU)[12]. MIMIC-IV encompasses de-identified electronic health records of intensive care unit (ICU) patients at Beth Israel Deaconess Medical Center (2008-2019). eICU includes de-identified electronic health records from 208 US ICUs (2014-2015),
representing a diverse ICU patient population. We used MIMIC-IV for development and eICU for external validation. We followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for reporting observational studies[13].

**Study Population**

We included adult, critically ill patients with sepsis who developed AKI. Following Kidney Disease Improving Global Outcomes (KDIGO) guidelines[14], we defined AKI as either a rise in serum creatinine of 0.3 mg/dL or more within 48 hours or an increase of at least 1.5 times the reference serum creatinine within 7 days, or a urine output of less than 0.5 ml/kg/h for at least a 6-hour time-period.

To determine reference creatinine, we first identified the baseline creatinine by calculating the median serum creatinine from measurements within 12 months before hospital admission[15, 16]. If unavailable, we followed the KDIGO guidelines to estimate baseline serum creatinine by back-calculating using the Modification of Diet in Renal Disease equation[17], while assuming an estimated glomerular filtration rate 75 ml/min per 1.73 m²[14]. We then chose the lower of baseline or admission creatinine as the reference creatinine[18]. Our specific criteria for inclusion were adults aged 18 years or older upon admission, who developed sepsis according to third international consensus definition[19, 20] within 24 hours of admission to intensive care unit (ICU)[21], and developed AKI within 48 hours after admission to ICU. We considered only the first ICU admission for those patients with multiple admissions.
We excluded patients with a history of end stage kidney disease or kidney transplant, lack of serum creatinine measurements within 48 hours after AKI onset, death or transfer out of the ICU within 48 hours of AKI onset, or those with missing fluid administration values from ICU admission to 24 hours after AKI onset. Details regarding the selection process employed in this study are given in Fig. 1.

Outcomes

The primary outcome of our study was early AKI reversal defined as the patient no longer meeting KDIGO criteria for AKI within 48 hours of AKI onset[14]. The secondary outcomes included sustained AKI reversal, defined as maintaining AKI reversal for 48 hours or longer [22], and MAKE at discharge defined as a composite of in-hospital death, new dialysis or persistent kidney dysfunction[23]. In consistence with previous literature, persistent kidney dysfunction was defined as the final inpatient serum creatinine value as ≥200% of reference creatinine[23].

Treatment
The treatment of interest in this study was the amount of IV fluids administered, including both crystalloids and colloids, from the onset of AKI to either early AKI reversal or up to 24 hours after AKI onset, whichever is sooner. We defined ‘restrictive fluid strategy’ as administering less than 500mL of IV fluids within this specified time frame (Fig. 2).

**Features**

We extracted data on patient demographics, such as age, sex, and race/ethnicity, and for vital signs, SOFA scores, vasopressor administration, use of mechanical ventilation, net fluid balance from ICU admission to onset of AKI. We also extracted data for laboratory values and administration of nephrotoxic medications[24] within the last 48 hours prior to AKI onset. Additionally, we collected data on treatment - the amount of IV fluids administered from the onset of AKI to either early reversal or up to 24 hours after AKI onset, whichever is sooner. Physiologically...
improbable values were removed based on inputs from content experts. For vital signs, laboratory values and SOFA scores, we collected the highest, lowest and latest values when multiple values were present. We only included features that were present in over 70% of the cohort. Missing data were imputed using the multivariate imputation by chained equations (MICE) method [25].

Development of Policy Tree Approach

We used a novel, machine learning guided strategy (‘Policy Tree’) to identify critically ill septic patients with AKI who would benefit from a restrictive fluid strategy. The development of policy tree approach employed a dual machine learning methodology. In the first step, we estimated individual treatment effects (ITE) to ascertain the impact restrictive fluid strategy in the critical initial phase post-AKI onset at the individual patient level[26]. Subsequently, we applied the policy tree algorithm[27] to construct a decision tree[28] -

Step 1 - Individual Treatment Effects Estimation: We utilized the causal forest[26] method to estimate ITE within our development cohort. This method is a widely recognized quasi-experimental approach for estimating treatment effects using observational data, as opposed to conducting actual experiments. The causal forest uniquely targets the prediction of unit-level conditional average treatment effects, focusing on maximizing the variance in treatment effects between nodes rather than minimizing prediction error. This process involves two critical steps to ensure accuracy and computational efficiency. Initially, it identifies optimal splits that maximize the expected difference in treatment effects. Following that, during the prediction phase, it estimates treatment effects by aggregating data from similar observations within the forest's leaves.

Step 2 - Policy Tree Algorithm: We then used the policy tree algorithm[27] to identify patients who would benefit in terms of early AKI reversal by adhering to restrictive fluid strategy. This algorithm constructs a hierarchical model that categorizes patients based on similar ITE within the same action node and distinct ITE across different action nodes. It considers ITE, relevant features for policy tree construction, the depth of the tree, and the minimum number of observations per node. The algorithm iteratively refines the feature splits to maximize the variance in ITE.

Statistical Analysis
We expressed continuous features as mean and standard deviation, while categorical features as proportions. We examined the differences across groups using bivariate analyses, including analysis of variance (ANOVA) for continuous variables and chi-square tests for categorical variables, with a P value of < .05 considered statistically significant across all statistical tests.

We then used logistic and linear regression models to assess the impact of adhering to personalized recommendation for restrictive fluid strategy on early AKI reversal, sustained AKI reversal, and major adverse kidney events (MAKE) at discharge. We adjusted these regression models for age, sex, race, reference serum creatinine, SOFA score at the time of sepsis onset, AKI stage at the time of AKI onset, and net fluid balance between ICU admission and AKI onset for each outcome.

All statistical analyses were performed using R software, version 4.3.0[29]. The study received approval from the Institutional Review Board at the Icahn School of Medicine at Mount Sinai (approval no. 19-00951).

RESULTS:

Study Population

Our study included 6,935 patients in MIMIC-IV as the development cohort, and 2,091 patients in eICU as the external validation cohort. The average age in the development cohort was 66.8 ± 15.9 years, with 57.1% males and 66.1% Whites. The average age in the external validation cohort was 66.5 ± 14.8 years with 57.0% males and 80.6% Whites. The baseline characteristics are shown in Table 1 and Supplementary Table S1.
Our policy tree identifies patients with AKI and sepsis who are likely to benefit from a restrictive fluid strategy, defined as administering less than 500mL of IV fluids within 24 hours of AKI onset or until early reversal if it occurs within 24 hours (Fig. 2). The key determinants identified for early AKI reversal were age, systolic blood pressure (SBP), respiratory rate, pCO2, net fluid balance, elements of basic metabolic panel (blood urea nitrogen (BUN), creatinine, calcium) and elements of complete blood count (white blood cells, red blood cells, hemoglobin and hematocrit). The primary decision point in the policy tree was based on the maximum BUN within 48 hours before AKI onset (Fig. 3).

The policy tree suggested benefit from restrictive fluid strategy after development of AKI among 6,223 (89.7%) patients in the development cohort and 1,844 (88.2%) patients in the external validation cohort. The baseline characteristics of these patients are shown in Table 1 and Supplementary Table S1. Among the patients identified to benefit from restrictive fluid therapy, only 812 (13%) patients in development cohort and 542 (29.4%) patients in external validation cohort received restrictive fluid therapy. Among patients identified to benefit from restrictive fluid strategy, those that received restrictive fluids were older, with lower net fluid balance and higher urine output from ICU admission to AKI in both development and external validation cohort (Table 2 and Supplementary Table S2).

Fig. 3 Policy Tree for Restrictive Fluid Strategy in Septic Patients with Acute Kidney Injury
Outcomes

**Primary Outcome:** In both development and external validation cohorts, patients suggested by policy tree to benefit from a restrictive fluid strategy who received restrictive fluids had significantly higher rates of early AKI reversal in comparison to those that were suggested to have a benefit from restrictive fluids but did not receive them – 79.9% vs. 43.0%; p<0.001 in development cohort; 48.2% vs. 39.6%; 0.001 in external validation cohort (Fig. 4a). On unadjusted analysis, restrictive fluid strategy among the patients identified to benefit from restrictive fluids, was associated with significantly greater odds of early AKI reversal in both development (OR 5.27; 95% CI: 4.40 – 6.31) and external validation (OR 1.41; 95% CI: 1.16 – 1.73) cohorts (Fig. 4b). This effect was consistent in adjusted analysis where restrictive fluid strategy among patients suggested to benefit from restrictive fluids was associated with greater odds of early AKI reversal in both development (OR 5.12; 95% CI: 4.26 – 6.17) and external validation cohorts (OR 1.41; 95% CI: 1.14 – 1.73) (Fig. 4b). In comparison, in both development and external validation cohorts, patients identified to have no benefit from a restrictive fluid strategy did not show any improvement in outcomes when they received restrictive fluids (Fig. 4a and 4b).

---

**Fig. 4** Impact of restrictive fluid strategy among patients stratified by predicted benefit from receipt of restrictive fluid strategy: a) Proportion, b) Odds ratio, i) In MIMIC-IV (Development Cohort), ii) in eICU (External Validation Cohort)
Secondary Outcomes: Among patients identified by the policy tree to benefit from a restrictive fluid strategy, both the development and external validation cohorts showed that those who received restrictive fluids had higher rates of sustained AKI reversal and lower rates of major acute kidney events (MAKE) at discharge compared to those who did not receive restrictive fluids (Fig. 4a). In the external validation cohort, among patients identified to benefit from restrictive fluids, 36.7% of those who received restrictive fluids achieved sustained AKI reversal, compared to only 27.4% of those who did not receive them (p<0.001). Additionally, only 29.3% of patients who received restrictive fluids developed major acute kidney events (MAKE) by discharge, compared to 35.1% of those who did not receive them (p=0.019). In the unadjusted analysis of the external validation cohort, use of restrictive fluids among patients identified to benefit from a restrictive fluid strategy was associated with a significantly higher odds sustained AKI reversal (OR 1.54; 95% CI: 1.24 – 1.90) and lower odds of developing MAKE at discharge (OR 0.77; 95% CI: 0.62 – 0.95). This effect remained consistent in the adjusted analysis, where a restrictive fluid strategy among patients identified to benefit from it was associated with significantly higher odds of sustained AKI reversal (OR 1.54; 95% CI: 1.24 – 1.91) and lower odds of MAKE at discharge (OR 0.78; 95% CI: 0.62 – 0.99). Patients identified as not deriving any benefit from restrictive fluid strategy showed no benefit from receiving restrictive fluids in both adjusted and unadjusted analyses (Fig. 4a and 4b).

DISCUSSION:

In this study we have developed and validated a novel, data-driven, causal machine learning strategy to identify critically ill patients with sepsis who develop AKI and would benefit from a restrictive fluid strategy. We show that among patients predicted to benefit from and administered restrictive fluids, there were increased odds of early AKI reversal and sustained AKI reversal, alongside lower odds of MAKE, even after adjusting for confounders.

Administration of IV fluids to improve cardiac output and consequently kidney blood flow, has been a cornerstone of therapy for AKI. This is based on the assumption that decrease in kidney blood flow is a major driver of AKI [30], However, there are 3 major observations which contradict this hypothesis.
First, even though fluid administration may increase cardiac output and renal blood flow, it does not lead to improvement in renal oxygen delivery or renal microvascular oxygenation[31, 32]. Second, fluid bolus does not always increase urine output. In a prospective, multicenter, observational study including 5 ICUs where patients with oliguria received IV fluids, improvement in urine output was seen in only half of the patients[4]. Third, kidney blood flow is not decreased in sepsis[33]. Instead, the pathogenesis of AKI in critically ill patients includes a complex interplay of inflammatory mediators[34-36], microcirculatory dysfunction[37] and metabolic reprogramming[38, 39]. These result in direct tubular injury, which is not reversible with administration of IV fluids.

IV fluid administration can lead to volume overload, often seen in AKI patients, and is associated with higher morbidity and mortality especially in AKI patients [40, 41]. This excess fluid can cause interstitial edema[42, 43], impaired blood flow and organ dysfunctions. Fluid overload also damages the endothelial glycocalyx layer which is crucial for vascular homeostasis and permeability. Inflammatory mediators in sepsis themselves lead to glycocalyx degradation, a process which is exacerbated by IV fluid resuscitation[44]. This glycocalyx damage increases local inflammation, tissue edema and further end organ injury including acute respiratory distress syndrome (ARDS) and AKI[45]. Fluid overload is also a known risk-factor for development of intra-abdominal hypertension[46], which further contributes to worsening AKI [47].

Thus, there is an increasing focus on minimizing the use of IV fluids in critically ill patients. A randomized study comparing conservative and usual fluid therapy in patients with ARDS found no difference in 60-day mortality[8]. However, the conservative group had improved oxygenation index, lung injury score, lower plateau pressures, increased number of ventilator free days and ICU free days. Studies in patients with sepsis have also found a shorter duration of mechanical ventilation and a trend towards lower mortality for patients managed with conservative fluid strategy [48].

The REVERSE-AKI trial directly evaluated the role of restrictive fluid therapy for management of AKI[10]. This multicenter, randomized, controlled study enrolled adult, critically ill patients with AKI not requiring dialysis. The trial aimed to attain a negative fluid balance in the intervention arm following randomization. By 24 hours, the restrictive fluid group had a cumulative fluid balance of -416mL vs 409mL in the usual care group (p<0.001). At 72
hours, this balance was -1080mL vs 61mL (p=0.03). The trial found that the restrictive fluid group had lower
dialysis rates (13% vs 30%; p=0.04) and a trend towards lower duration of AKI (median 2 days vs 3 days; p=0.07).
This trial demonstrated that restrictive fluid management in AKI is feasible and may improve outcomes. Building on
this, our study identifies critically ill septic patients with AKI who would benefit from restrictive fluid therapy. We
have used Policy Tree Algorithm[27], a cutting-edge causal machine learning technique to develop a data driven
approach to identify these patients. We show that when identified using this approach, patients who do get restrictive
fluids have much higher rates of both early AKI and sustained AKI reversal, and lower rates of MAKE at discharge.
Validation of this approach in an external database is a significant strength of this study.

It is important to acknowledge the limitations of our study. First, this is a retrospective study and validation
of this approach in prospective, randomized studies is important. Second, we chose the cut-off of 500mL for
restrictive fluids based prior literature suggesting 500mL is the typical amount of fluid given during a fluid
challenge[3], and was also the amount given in restrictive fluid groups in prior studies[9, 49]. However, future work
could focus on different fluid cutoffs. Third, while we adjusted for potential confounders, unmeasured and residual
confounding cannot be eliminated.

In conclusion, in this study using a causal learning approach we developed and validated a strategy to
identify critically ill patients with AKI who would benefit from a restrictive fluid strategy. This approach should be
considered in future prospective, pragmatic trials to improve outcomes of septic patients with AKI.
FUNDING:

This work was supported by the National Institutes of Health (NIH) grants K08DK131286 awarded to A.S., R01DK108803, U01HG007278, U01HG009610, and U01DK116100 awarded to G.N.N. and T32DK007757 and TL1DK136048 awarded to W.O. The content is solely the responsibility of the authors and does not necessarily represent the views of the NIH.

AUTHOR CONTRIBUTIONS:

WO and AS designed and conceptualized the study. WO, KT, and HK performed data collection and analysis. WO and AS interpreted the data analyses. WO and AS wrote the first draft of the manuscript. All authors critically revised the manuscript for important intellectual content and read and approved the final version. All authors gave final approval for the version to be published. WO is first author, GNN and AS and co-senior authors.

STATEMENT AND DECLARATION:

Competing Interests

GNN is a founder of Renalytix, Pensieve, Verici and provides consultancy services to AstraZeneca, Reata, Renalytix, Siemens Healthineer and Variant Bio, serves a scientific advisory board member for Renalytix and Pensieve. He also has equity in Renalytix, Pensieve and Verici. LC is a consultant for Vifor Pharma INC and has received honorarium from Fresenius Medical Care. JAK reports receiving consulting fees from Astute Medical/bioMerieux, Astellas, Alexion, Chugai Pharma, Novartis, Mitsubishi Tenabe and GE Healthcare and is a Full-time employee of Spectral Medical. All remaining authors have declared no conflicts of interest.
REFERENCES:


Table 1. Baseline Characteristics of Patients in Development (MIMIC-IV) and External Validation (eICU) Cohorts.

<table>
<thead>
<tr>
<th></th>
<th>Development cohort (MIMIC-IV)</th>
<th>External validation cohort (eICU)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Identified to have no benefit from restrictive fluid strategy (N= 712)</td>
<td>Identified to benefit from restrictive fluid strategy (N= 6,223)</td>
<td>Total (N= 6,935)</td>
<td>0.248</td>
</tr>
<tr>
<td>Age, year, (mean±SD)</td>
<td>67.49 ± 15.19</td>
<td>66.77 ± 15.98</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td>&lt;0.001</td>
<td>0.375</td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>437 (61.4%)</td>
<td>4150 (66.7%)</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>100 (14.0%)</td>
<td>533 (8.6%)</td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>20 (2.8%)</td>
<td>182 (2.9%)</td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>155 (21.8%)</td>
<td>1358 (21.8%)</td>
<td></td>
</tr>
<tr>
<td>Gender - Male, n (%)</td>
<td>412 (57.9%)</td>
<td>3548 (57.0%)</td>
<td>0.664</td>
</tr>
<tr>
<td>Baseline creatinine, mg/dL, (mean±SD)</td>
<td>2.16 ± 2.30</td>
<td>1.15 ± 0.93</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>AKI stage, n (%)</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>473 (66.4%)</td>
<td>5593 (89.9%)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>35 (4.9%)</td>
<td>409 (6.6%)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>204 (28.7%)</td>
<td>221 (3.6%)</td>
<td></td>
</tr>
<tr>
<td>SOFA at the time of sepsis onset, (mean±SD)</td>
<td>5.08 ± 2.82</td>
<td>4.45 ± 2.36</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Vasopressors², n (%)</td>
<td>250 (35.1%)</td>
<td>3111 (50.0%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mechanical ventilation³, n (%)</td>
<td>2796 (51.7%)</td>
<td>315 (38.8%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Nephrotoxic drugs administration⁴, n (%)</td>
<td>149 (20.9%)</td>
<td>1402 (22.5%)</td>
<td>0.331</td>
</tr>
</tbody>
</table>

Abbreviation: AKI (acute kidney injury), SOFA (sequential organ failure assessment)

²: Measurements from the last 48 hours prior to AKI onset
B: Measurements from ICU admission to AKI onset
Table 2. Baseline Characteristics of Patients Identified to Benefit from Restrictive Fluids: Development (MIMIC-IV) and External Validation (eICU) cohorts.

<table>
<thead>
<tr>
<th></th>
<th>Development cohort (MIMIC-IV)</th>
<th></th>
<th></th>
<th></th>
<th>External validation cohort (eICU)</th>
<th></th>
<th></th>
<th>p value</th>
<th></th>
<th></th>
<th></th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unrestricted fluid intake</td>
<td>Restricted fluid</td>
<td>Total</td>
<td>p value</td>
<td>Unrestricted fluid intake</td>
<td>Restricted fluid</td>
<td>Total</td>
<td></td>
<td>Unrestricted fluid</td>
<td>Restricted fluid</td>
<td>Total</td>
<td></td>
</tr>
<tr>
<td></td>
<td>group (N=5,411)</td>
<td>intake group (N=812)</td>
<td>(N=6,223)</td>
<td></td>
<td>group (N=1,302)</td>
<td>intake group (N=542)</td>
<td>(N=1844)</td>
<td></td>
<td>intake group (N=1,302)</td>
<td>intake group (N=542)</td>
<td>(N=1844)</td>
<td></td>
</tr>
<tr>
<td>Age, year, (mean±SD)</td>
<td>66.55 ± 15.91</td>
<td>68.19 ± 16.44</td>
<td>66.77 ± 15.98</td>
<td>0.007</td>
<td>65.41 ± 15.02</td>
<td>67.72 ± 14.44</td>
<td>66.09 ± 14.88</td>
<td>0.002</td>
<td>65.41 ± 15.02</td>
<td>67.72 ± 14.44</td>
<td>66.09 ± 14.88</td>
<td>0.002</td>
</tr>
<tr>
<td>Race, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.872</td>
<td></td>
<td></td>
<td></td>
<td>0.03</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>3601 (66.5%)</td>
<td>549 (67.6%)</td>
<td>4150 (66.7%)</td>
<td></td>
<td>1034 (79.4%)</td>
<td>458 (84.5%)</td>
<td>1492 (80.9%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>462 (8.5%)</td>
<td>71 (8.7%)</td>
<td>533 (8.6%)</td>
<td></td>
<td>135 (10.4%)</td>
<td>51 (9.4%)</td>
<td>186 (10.1%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hispanic</td>
<td>158 (2.9%)</td>
<td>24 (3.0%)</td>
<td>182 (2.9%)</td>
<td></td>
<td>28 (2.2%)</td>
<td>8 (1.5%)</td>
<td>36 (2.0%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>1190 (22.0%)</td>
<td>168 (20.7%)</td>
<td>1358 (21.8%)</td>
<td></td>
<td>105 (8.1%)</td>
<td>25 (4.6%)</td>
<td>130 (7.0%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender - Male, n (%)</td>
<td>3098 (57.3%)</td>
<td>450 (55.4%)</td>
<td>3548 (57.0%)</td>
<td>0.325</td>
<td>755 (58.0%)</td>
<td>299 (55.2%)</td>
<td>1054 (57.2%)</td>
<td>0.265</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline creatinine, mg/dL, (mean±SD)</td>
<td>1.15 ± 0.92</td>
<td>1.12 ± 1.03</td>
<td>1.15 ± 0.93</td>
<td>0.437</td>
<td>0.90 ± 0.17</td>
<td>0.87 ± 0.18</td>
<td>0.89 ± 0.17</td>
<td>0.002</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AKI stage, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.019</td>
<td></td>
<td></td>
<td></td>
<td>0.211</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>4841 (89.5%)</td>
<td>752 (92.6%)</td>
<td>5593 (89.9%)</td>
<td></td>
<td>858 (65.9%)</td>
<td>376 (69.4%)</td>
<td>1234 (66.9%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>368 (6.8%)</td>
<td>41 (5.0%)</td>
<td>409 (6.6%)</td>
<td></td>
<td>274 (21.0%)</td>
<td>110 (20.3%)</td>
<td>384 (20.8%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>202 (3.7%)</td>
<td>19 (2.3%)</td>
<td>221 (3.6%)</td>
<td></td>
<td>170 (13.1%)</td>
<td>56 (10.3%)</td>
<td>226 (12.3%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOFA at the time of sepsis onset, (mean±SD)</td>
<td>4.56 ± 2.41</td>
<td>3.76 ± 1.85</td>
<td>4.45 ± 2.36</td>
<td>&lt; 0.001</td>
<td>4.66 ± 2.41</td>
<td>4.85 ± 2.53</td>
<td>4.71 ± 2.45</td>
<td>0.119</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vasopressors, n (%)</td>
<td>2796 (51.7%)</td>
<td>315 (38.8%)</td>
<td>3111 (50.0%)</td>
<td>&lt; 0.001</td>
<td>197 (15.1%)</td>
<td>108 (19.9%)</td>
<td>305 (16.5%)</td>
<td>0.012</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanical ventilation, n (%)</td>
<td>2796 (51.7%)</td>
<td>315 (38.8%)</td>
<td>3111 (50.0%)</td>
<td>&lt; 0.001</td>
<td>197 (15.1%)</td>
<td>108 (19.9%)</td>
<td>305 (16.5%)</td>
<td>0.012</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nephrotoxic drugs, n (%)</td>
<td>149 (20.9%)</td>
<td>1402 (22.5%)</td>
<td>1551 (22.4%)</td>
<td>0.331</td>
<td>169 (68.4%)</td>
<td>1282 (69.5%)</td>
<td>1451 (69.4%)</td>
<td>0.724</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviation: AKI (acute kidney injury), SOFA (sequential organ failure assessment)

A: Measurements from the last 48 hours prior to AKI onset

B: Measurements from ICU admission to AKI onset